• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Tempus AI Inc.

    5/23/25 6:31:57 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email
    8-K
    false 0001717115 0001717115 2025-05-20 2025-05-20
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 20, 2025

     

     

    Tempus AI, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-42130   47-4903308
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    600 West Chicago Avenue  
    Suite 510  
    Chicago, Illinois   60654
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: 800 976-5448

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     


    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange
    on which registered

    Class A common stock, $0.0001 par value per share   TEM   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    Tempus AI, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on May 20, 2025. In accordance with the Company’s amended and restated certificate of incorporation, stockholders of the Company’s Class A common stock (“Class A stockholders”) have one vote per share and stockholders of the Company’s Class B common stock (“Class B stockholders”) have 30 votes per share. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. These proposals are described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 7, 2025.

    Proposal 1. Election of Directors.

    The Company’s Class A stockholders and Class B stockholders, voting together as a single class, elected the nine directors listed below, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results are as follows:

     

    Name

       Votes For      Votes Withheld      Broker Non-Votes  

    Eric Lefkofsky

         232,428,831        10,652,429        16,157,514  

    Peter J. Barris

         231,351,586        11,729,674        16,157,514  

    Eric D. Belcher

         240,323,799        2,757,461        16,157,514  

    Jennifer A. Doudna, Ph.D.

         231,800,837        11,280,423        16,157,514  

    David R. Epstein

         231,738,670        11,342,590        16,157,514  

    Wayne A.I. Frederick, M.D.

         240,255,211        2,826,049        16,157,514  

    Scott Gottlieb, M.D.

         231,702,607        11,378,653        16,157,514  

    Theodore J. Leonsis

         231,044,224        12,037,036        16,157,514  

    Nadja West, M.D.

         231,670,196        11,411,064        16,157,514  

    Proposal 2. Ratification of the Appointment of Independent Registered Public Accounting Firm.

    The Company’s Class A stockholders and Class B stockholders, voting together as a single class, ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

    258,785,082   257,488   196,204

    Proposal 3. Approval of Reincorporation.

    The Company’s Class A stockholders and Class B stockholders, voting together as a single class, approved the reincorporation of the Company from the State of Delaware to the State of Nevada by conversion (the “Reincorporation”). The Company’s Board of Directors retains the discretion to abandon the Reincorporation. If completed, upon the completion of the Reincorporation, the Company will become a Nevada corporation and will continue to operate its business under its current name, “Tempus AI, Inc.” The final voting results are as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    229,810,726   13,226,368   44,166   16,157,514

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Tempus AI, Inc.
    Dated: May 23, 2025  
        By:  

    /s/ James Rogers

          James Rogers
          Chief Financial Officer
    Get the next $TEM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    12/13/2024$60.00Outperform
    Wolfe Research
    12/9/2024$74.00Buy
    Guggenheim
    11/11/2024$45.00 → $65.00Buy → Hold
    Stifel
    10/2/2024$45.00 → $60.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration leverages Tempus' AI-powered data analytics platform, Lens, to analyze and restructure the Center's repository of genomic data. Together, the Center and Tempus teams will work to uncover genomic patterns that have the potential to advance the understanding of Alzheimer's disease, investigate the ge

      6/12/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced xM for treatment response monitoring (TRM), a liquid biopsy assay intended to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in advanced solid tumors. xM for TRM is the newest addition to Tempus' growing portfolio of sensitive assays for monitoring molecular response and minimal residual disease (MRD). It is currently available for research use only, with clinical availability expected later this year. In 2023, an estimated 56.55% of patients with advanced or metastatic cancers were eligible for ICIs, with a corresponding est

      6/2/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Introducing Tempus One in the EHR with Integrated Guidelines

      The AI-enabled clinical assistant is available to query patient data across the EHR as well as build custom agents to maximize workflow Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR

      6/1/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    SEC Filings

    See more
    • SEC Form 8-K filed by Tempus AI Inc.

      8-K - Tempus AI, Inc. (0001717115) (Filer)

      5/23/25 6:31:57 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 144 filed by Tempus AI Inc.

      144 - Tempus AI, Inc. (0001717115) (Subject)

      5/21/25 7:23:49 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 144 filed by Tempus AI Inc.

      144 - Tempus AI, Inc. (0001717115) (Subject)

      5/21/25 7:20:13 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 5:00:02 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 4:30:28 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

      SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

      8/20/24 4:27:51 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Reporting)

      8/20/24 4:17:55 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Leonsis Theodore sold $13,927,976 worth of shares (205,847 units at $67.66) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      6/13/25 4:15:10 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Chief Operating Officer Fukushima Ryan sold $1,245,764 worth of shares (20,000 units at $62.29), decreasing direct ownership by 2% to 856,640 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      6/5/25 4:15:35 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Director Doudna Jennifer A sold $30,802 worth of Class A Comnmon Stock (558 units at $55.20), decreasing direct ownership by 2% to 27,179 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      6/4/25 4:15:27 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Tempus AI with a new price target

      BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

      4/21/25 8:39:11 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by Analyst with a new price target

      Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

      2/25/25 7:14:46 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by William Blair

      William Blair downgraded Tempus AI from Outperform to Mkt Perform

      2/12/25 7:11:34 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Financials

    Live finance-specific insights

    See more
    • Tempus Reports First Quarter 2025 Results

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

      5/6/25 4:01:00 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report First Quarter 2025 Financial Results on May 6

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307

      4/24/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i

      2/11/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology